Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Gilead Sciences CFO Dickinson sells $514,410 in stock

Gilead Sciences CFO Dickinson sells $514,410 in stock

Andrew D. Dickinson, Gilead Sciences' Chief Financial Officer, disposed of 3,000 shares of the company's stock on November 16, 2026, for a total of $514,410. The sale was executed via a pre-approved Rule 10b5-1 trading plan, which Dickinson established on August 29, 2024. At the time of the transaction, each share was worth $171.47.

The stock's price is currently trading near its 52-week peak of $176.58, following a robust 33% gain over the past six months. Despite this, analysts believe the stock may be overvalued relative to its estimated fair value. Dickinson now personally owns 158,096 shares of Gilead Sciences. The company's latest quarter saw impressive financials, with revenue of $8.3 billion, surpassing analyst estimates by 6%.

Earnings per share also exceeded expectations, at $2.55, a 15% improvement over forecasts. Gilead Sciences' HIV portfolio has been a significant driver of this success, contributing to a $500 million revenue increase and prompting a $900 million increase in the company's fiscal 2026 earnings guidance. Recent analyst activity has been bullish, with firms like UBS and TD Cowen raising price targets and maintaining Buy ratings.

These positive developments highlight Gilead Sciences' strong performance and promising future outlook.

Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at investing.com →

More in Finance & Markets

More from Wednesday 18 November →